NME2 and neoplasm: To evaluate whether NME2 tumor expression has a direct role in promoting resistance to Enzalutamide in vivo, we sought to test the hypothesis that loss of NME2 in Enzalutamide-resistant C42B cells is sufficient to restore Enzalutamide sensitivity.